![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Greenlights Fourth Batch of J&J Vaccine From Troubled Emergent Plant
FDA Greenlights Fourth Batch of J&J Vaccine From Troubled Emergent Plant
![Green_Light.gif](https://www.fdanews.com/ext/resources/test/Device_Images5/Green_Light.gif?t=1625610540&width=430)
The FDA has authorized the use of a fourth additional batch of the Johnson & Johnson (J&J) COVID-19 vaccine manufactured at the troubled Emergent BioSolutions facility in Bayview, Md. The batch of bulk drug substance can make up to 15 million doses of the J&J vaccine.
An estimated 75 million doses of J&J’s vaccine produced at Emergent were ordered destroyed by the FDA following the discovery that many had been cross-contaminated with AstraZeneca vaccines, also made at the facility.
The agency has not yet fully cleared the facility to produce vaccines. J&J is now overseeing production at the Bayview facility and the FDA has instructed AZ to find another producer for its vaccine to avoid any possibility of future cross-contamination of products at the plant.
Upcoming Events
-
18Jul
-
21Oct